Cancer Control and Prevention Protocols, Treatment Protocols
Adjuvant Breast, Breast
Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer
Eligible for screening study DCP 001
Effective December 31st, 2019, study A221405 is permanently closed to new patient registration.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or email@example.com for additional information.